These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 19754922)

  • 21. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
    Shimon I
    Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological properties of two cloned somatostatin receptors.
    Rens-Domiano S; Law SF; Yamada Y; Seino S; Bell GI; Reisine T
    Mol Pharmacol; 1992 Jul; 42(1):28-34. PubMed ID: 1353250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells.
    Liu HL; Huo L; Wang L
    Acta Pharmacol Sin; 2004 Oct; 25(10):1380-6. PubMed ID: 15456543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
    Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
    J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.
    Casarini AP; Jallad RS; Pinto EM; Soares IC; Nonogaki S; Giannella-Neto D; Musolino NR; Alves VA; Bronstein MD
    Pituitary; 2009; 12(4):297-303. PubMed ID: 19330452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20.
    Tallent M; Liapakis G; O'Carroll AM; Lolait SJ; Dichter M; Reisine T
    Neuroscience; 1996 Apr; 71(4):1073-81. PubMed ID: 8684611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells.
    Kailey B; van de Bunt M; Cheley S; Johnson PR; MacDonald PE; Gloyn AL; Rorsman P; Braun M
    Am J Physiol Endocrinol Metab; 2012 Nov; 303(9):E1107-16. PubMed ID: 22932785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.
    Jaquet P; Ouafik L; Saveanu A; Gunz G; Fina F; Dufour H; Culler MD; Moreau JP; Enjalbert A
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3268-76. PubMed ID: 10487698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
    Turner HE; Lindsell DR; Vadivale A; Thillainayagam AV; Wass JA
    Eur J Endocrinol; 1999 Dec; 141(6):590-4. PubMed ID: 10601961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly.
    Stolk MF; van Erpecum KJ; Koppeschaar HP; de Bruin WI; Jansen JB; Lamers CB; van Berge Henegouwen GP
    Gut; 1993 Jun; 34(6):808-13. PubMed ID: 8314514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion.
    Ren SG; Taylor J; Dong J; Yu R; Culler MD; Melmed S
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4239-45. PubMed ID: 12970293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective Interactions of Mouse Melanocortin Receptor Accessory Proteins with Somatostatin Receptors.
    Wang M; Xu J; Lei XW; Zhang C; Liu SY; Jin LN; Zhang C
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes.
    Gong AY; Tietz PS; Muff MA; Splinter PL; Huebert RC; Strowski MZ; Chen XM; LaRusso NF
    Am J Physiol Cell Physiol; 2003 May; 284(5):C1205-14. PubMed ID: 12676656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms.
    Buscail L; Estève JP; Saint-Laurent N; Bertrand V; Reisine T; O'Carroll AM; Bell GI; Schally AV; Vaysse N; Susini C
    Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1580-4. PubMed ID: 7878022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of somatostatin receptor subtypes mediating inhibition of nutrient-stimulated gastric acid and gastrin in dogs.
    Fung LC; Greenberg GR
    Regul Pept; 1997 Feb; 68(3):197-203. PubMed ID: 9100287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of somatostatin receptor subtype 2 inhibits acid secretion in rats.
    Lloyd KC; Wang J; Aurang K; Grönhed P; Coy DH; Walsh JH
    Am J Physiol; 1995 Jan; 268(1 Pt 1):G102-6. PubMed ID: 7840190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of somatostatin receptor subtypes.
    Bruns C; Weckbecker G; Raulf F; Lübbert H; Hoyer D
    Ciba Found Symp; 1995; 190():89-101; discussion 101-10. PubMed ID: 7587655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Bottoni A; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Taylor JE; Culler MD; Cavazzini L; degli Uberti EC
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5181-8. PubMed ID: 15472224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of agonist-dependent somatostatin receptor subtype 2 trafficking in neuroendocrine cells.
    Alshafie W; Pan YE; Kreienkamp HJ; Stroh T
    Endocrine; 2020 Sep; 69(3):655-669. PubMed ID: 32383089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.